From left to right: José Luis Jorcano, General Director of Genoma España, Katharina Schropp, Director of Business Development & Conferences at EBD Group, Jesús Sainz, President of PromoMadrid, José María Fernández Sousa, President of Zeltia, and Fernando Peláez, Director of the Center of Investigations of Merck Sharp & Dohme.
Leading executives from Madrid’s biotech cluster met Read more »
Having recently signed the big pharma deal for its lead product that all venture-backed companies strive for, MacroGenics has secured its short-term future, with a number of out-licensing opportunities still on the table for the rest of its pipeline.
Speaking to EP Vantage at BIO Europe Spring, Gary Fanger, Vice President, Business Development, commented that following Read more »
Biomarkers are still in early stages of discovery, and more importantly, validation. Yet what is already clear is the potential to link an indicator of a disease state with therapeutics for that disease will transform how and why medications are prescribed in the future.
A diagnostic tool linked to a drug is a disruptive technology for Read more »
In-licensing deals dominate the headlines in bio-pharma partnering, but the news announced at BIO-Europe Spring 2008 that at least two big pharma companies are now looking to out-license drug development programs takes deal-making to a new level.
In the plenary session on new R&D and Licensing Strategies, both Dr. Greg Wiederrecht, Vice President for External Scientific Read more »
What does it take to support partnering for Life Science on a scale as large and intensive as BIO-Europe Spring 2008?
The partneringONE software from EBD Group virtually connects 1,400 participants starting six weeks ahead of the event.
But suddenly during the three days in Madrid, it all comes together in the real world as participants Read more »
Novosom AG was able to simultaneously announce two major developments at BIO-Europe 2008 that chief executive Elias Papatheodorou said showed the company is now accelerating its efforts “to turn a novel enabling delivery method into a product generating engine.”
Papatheodorou said that this week the company had received patents protecting its technology that utilizes single strands Read more »
People speak a lot about how a deal is structure and risk-sharing, but these subjects are really downstream of the issues that take the most time in negotiations, according to Joseph S. Dillon, the Senior Vice President for Corporate Development and Valuations at MattsonJack.
During an Interactive Workshop at BIO-Europe Spring 2008 Dillon offered a series Read more »
With the news of positive interim phase IIa trial data from Vertex’s VX-770 sufferers from cystic fibrosis now face the prospect of having a drug that could actually improve their condition, rather than relying on the current range of treatments that just slow disease progression.
Last week, Vertex announced that 20 patients using the new drug, Read more »
Newsletter